Schizophrenia-Like Symptoms in Narcolepsy Type 1: Shared and Distinctive Clinical Characteristics

Neuropsychobiology

Volumn 71, Issue 4, 2015, Pages 218-224

  Plazzi, Giuseppe ^a,b   Fabbri, Chiara ^a   Pizza, Fabio ^a,b   Serretti, Alessandro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b IRCCS ISTITUTO DELLE SCIENZE NEUROLOGICHE DI BOLOGNA   (Italy)

Author keywords

Anxiety; Delusion; Differential diagnosis; Dissociation; Hallucination; Narcolepsy; Psychosis; Schizophrenia; Sleep

Indexed keywords

MODAFINIL; OXYBATE SODIUM; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; ARTICLE; AUDITORY HALLUCINATION; BODY MASS; CATAPLEXY; CLINICAL ARTICLE; COMORBIDITY; CROSS-SECTIONAL STUDY; DELAYED DIAGNOSIS; DIAGNOSTIC ERROR; DISEASE DURATION; DISSOCIATIVE EXPERIENCES SCALE; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; HYPNAGOGIC HALLUCINATION; ILLUSION; MALE; NARCOLEPSY; NARCOLEPSY TYPE 1; OBSERVATIONAL STUDY; ONSET AGE; PARANOIA; PARASOMNIA; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; STATE TRAIT ANXIETY INVENTORY; SUICIDAL IDEATION; VISUAL HALLUCINATION; DELUSIONS; HALLUCINATIONS; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE;

ADULT; DELUSIONS; FEMALE; HALLUCINATIONS; HUMANS; MALE; MIDDLE AGED; NARCOLEPSY; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA;

EID: 84939508147     PISSN: 0302282X     EISSN: 14230224     Source Type: Journal    
DOI: 10.1159/000432400     Document Type: Article

References (46)

1. Douglass AB, Hays P, Pazderka F, Russell JM: Florid refractory schizophrenias that turn out to be treatable variants of HLA-associated narcolepsy. J Nerv Ment Dis 1991; 179: 12-17.
2. Bhat SK, Galang R: Narcolepsy presenting as schizophrenia. Am J Psychiatry 2002; 159: 1245.
3. Szucs A, Janszky J, Hollo A, Migleczi G, Halasz P: Misleading hallucinations in unrecognized narcolepsy. Acta Psychiatr Scand 2003; 108: 314-316.
4. Talih FR: Narcolepsy presenting as schizophrenia: a literature review and two case reports. Innov Clin Neurosci 2011; 8: 30-34.
5. Jardri R, Bartels-Velthuis AA, Debbane M, et al: From phenomenology to neurophysiological understanding of hallucinations in children and adolescents. Schizophr Bull 2014; 40(suppl 4):S221-S232.
6. Sarkanen T, Niemela V, Landtblom AM, Partinen M: Psychosis in patients with narcolepsy as an adverse effect of sodium oxybate. Front Neurol 2014; 5: 136.
7. Canellas F, Lin L, Julia MR, et al: Dual cases of type 1 narcolepsy with schizophrenia and other psychotic disorders. J Clin Sleep Med 2014; 10: 1011-1018.
8. Chen MH, Bai YM, Chen YS, Huang KL, Hsu JW, Su TP: Comorbidity of narcolepsy and schizophrenia in an adolescent patient. J Chin Med Assoc 2014; 77: 598-600.
9. Huang YS, Guilleminault C, Chen CH, Lai PC, Hwang FM: Narcolepsy-cataplexy and schizophrenia in adolescents. Sleep Med 2014; 15: 15-22.
10. Szakacs A, Hallbook T, Tideman P, Darin N, Wentz E: Psychiatric comorbidity and cognitive profile in children with narcolepsy with or without association to the H1N1 influenza vaccination. Sleep 2015; 28: 615-621.
11. Thorpy MJ, Krieger AC: Delayed diagnosis of narcolepsy: characterization and impact. Sleep Med 2014; 15: 502-507.
12. Longstreth WT Jr, Koepsell TD, Ton TG, Hendrickson AF, van Belle G: The epidemiology of narcolepsy. Sleep 2007; 30: 13-26.
13. American Academy of Sleep Medicine: International Classification of Sleep Disorders, ed 3. Darien, AASM, 2014.
14. Dauvilliers Y, Arnulf I, Mignot E: Narcolepsy with cataplexy. Lancet 2007; 369: 499-511.
15. Moturi S, Ivanenko A: Complex diagnostic and treatment issues in psychotic symptoms associated with narcolepsy. Psychiatry (Edgmont) 2009; 6: 38-44.
16. Walterfang M, Upjohn E, Velakoulis D: Is schizophrenia associated with narcolepsy? Cogn Behav Neurol 2005; 18: 113-118.
17. Mansukhani MP, Kotagal S: Sodium oxybate in the treatment of childhood narcolepsy-cataplexy: a retrospective study. Sleep Med 2012; 13: 606-610.
18. Blaivas AJ, Patel R, Hom D, Antigua K, Ashtyani H: Quantifying microsleep to help assess subjective sleepiness. Sleep Med 2007; 8: 156-159.
19. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 5. Washington, American Psychiatric Association, 2013.
20. Llewellyn S: In two minds? Is schizophrenia a state 'trapped' between waking and dreaming? Med Hypotheses 2009; 73: 572-579.
21. Fortuyn HA, Lappenschaar MA, Furer JW, et al: Anxiety and mood disorders in narcolepsy: a case-control study. Gen Hosp Psychiatry 2010; 32: 49-56.
22. Naidu K, van Staden WC, van der Linde M: Severity of psychotic episodes in predicting concurrent depressive and anxiety features in acute phase schizophrenia. BMC Psychiatry 2014; 14: 166.
23. Vignatelli L, Plazzi G, Peschechera F, Delaj L, D'Alessandro R: A 5-year prospective cohort study on health-related quality of life in patients with narcolepsy. Sleep Med 2011; 12: 19-23.
24. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B: Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011; 70: 663-671.
25. Grosskopf A, Muller N, Malo A, Wank R: Potential role for the narcolepsy- and multiple sclerosis-associated HLA allele DQB1∗0602 in schizophrenia subtypes. Schizophr Res 1998; 30: 187-189.
26. Singh AK, Mahlios J, Mignot E: Genetic association, seasonal infections and autoimmune basis of narcolepsy. J Autoimmun 2013; 43: 26-31.
27. Pizza F, Magnani M, Indrio C, Plazzi G: The hypocretin system and psychiatric disorders. Curr Psychiatry Rep 2014; 16: 433.
28. Partinen M, Kornum BR, Plazzi G, Jennum P, Julkunen I, Vaarala O: Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination. Lancet Neurol 2014; 13: 600-613.
29. Khandaker GM, Zimbron J, Lewis G, Jones PB: Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies. Psychol Med 2013; 43: 239-257.
30. Nielsen PR, Benros ME, Mortensen PB: Hospital contacts with infection and risk of schizophrenia: a population-based cohort study with linkage of Danish national registers. Schizophr Bull 2014; 40: 1526-1532.
31. Khandaker GM, Stochl J, Zammit S, Lewis G, Jones PB: Childhood Epstein-Barr virus infection and subsequent risk of psychotic experiences in adolescence: a population-based prospective serological study. Schizophr Res 2014; 158: 19-24.
32. Levite M: Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjögren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy. J Neural Transm 2014; 121: 1029-1075.
33. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4, rev. Washington, American Psychiatric Association, 2002.
34. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276.
35. Kay SR, Opler LA, Lindenmayer JP: Reliability and validity of the Positive and Negative Syndrome Scale for schizophrenics. Psychiatry Res 1988; 23: 99-110.
36. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
37. Carlson EB, Putnam FW, Ross CA, et al: Validity of the Dissociative Experiences Scale in screening for multiple personality disorder: a multicenter study. Am J Psychiatry 1993; 150: 1030-1036.
38. Speilberger C, Gorsuch R, Lushene R, Vagg P, Jacobs G: Manual for the State-Trait Anxiety Inventory. Palo Alto, Consulting Psychologists Press, 1983.
39. Dahmen N, Kasten M, Mittag K, Muller MJ: Narcoleptic and schizophrenic hallucinations. Implications for differential diagnosis and pathophysiology. Eur J Health Econ 2002; 3(suppl 2):S94-S98.
40. Nishino S: Clinical and neurobiological aspects of narcolepsy. Sleep Med 2007; 8: 373-399.
41. Fortuyn HA, Lappenschaar GA, Nienhuis FJ, et al: Psychotic symptoms in narcolepsy: phenomenology and a comparison with schizophrenia. Gen Hosp Psychiatry 2009; 31: 146-154.
42. Ohayon MM: Narcolepsy is complicated by high medical and psychiatric comorbidities: a comparison with the general population. Sleep Med 2013; 14: 488-492.
43. Chien J, Ostermann G, Turkel SB: Sodium oxybate-induced psychosis and suicide attempt in an 18-year-old girl. J Child Adolesc Psychopharmacol 2013; 23: 300-301.
44. Ortega-Albas JJ, Lopez-Bernabe R, Garcia AL, Gomez JR: Suicidal ideation secondary to sodium oxybate. J Neuropsychiatry Clin Neurosci 2010; 22: 352r.e26-352.e26.
45. Pelidou SH, Giannopoulos S, Lagos G, Kyritsis AP: Agenesis of the corpus callosum associated with narcolepsy-cataplexy. Sleep Med 2009; 10: 256-258.
46. Steinmann S, Leicht G, Mulert C: Interhemispheric auditory connectivity: structure and function related to auditory verbal hallucinations. Front Hum Neurosci 2014; 8: 8:55.